Physician profile
Ram Mittal
NPI 1306893516
$14,935.40
in general payments reported to CMS, 2019-2025
36 companies · $2,879 in 2025
The $2,879 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $975 · 2021: $2,493 · 2022: $2,413 · 2023: $2,269 · 2024: $2,458 · 2025: $2,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,555 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,555.04 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,173.27 | 2019-2025 | |
| Gilead Sciences, INC. | $2,615.11 | 2019-2025 | Vemlidy, Livdelzi, Epclusa |
| Janssen Biotech, INC. | $1,123.18 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $956.05 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Aimmune Therapeutics, INC. | $645.71 | 2024-2025 | Zenpep, Vowst |
| Braintree Laboratories, INC. | $537.05 | 2019-2022 | |
| Pfizer INC. | $529.52 | 2019-2025 | |
| Ardelyx, INC. | $470.35 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $442.04 | 2019-2025 | Entyvio |
| Celgene Corporation | $404.83 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $248.19 | 2019-2024 | |
| Madrigal Pharmaceuticals | $241.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Cook Medical LLC | $196.01 | 2025 | Hemospray, Echotip Insight |
| Nestle Healthcare Nutrition INC. | $184.35 | 2023 | |
| Redhill Biopharma INC. | $133.08 | 2020-2024 | Talicia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $127.32 | 2021-2024 | Sucraid, Sucraid |
| Allergan, INC. | $122.16 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $107.07 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $105.24 | 2024-2025 | Vegzelma |
| Genzyme Corporation | $99.66 | 2022-2024 | |
| Lilly USA, LLC | $63.07 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $57.75 | 2025 | Iqirvo |
| Shionogi INC | $48.56 | 2019-2020 | |
| Vivus LLC | $37.39 | 2022-2024 | Pancreaze |
| Merck Sharp & Dohme LLC | $36.82 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $32.83 | 2019-2021 | |
| Orphalan INC | $29.36 | 2025 | Cuvrior |
| Albireo Pharma, INC. | $25.84 | 2024 | Bylvay |
| Echosens North America, INC. | $23.65 | 2024 | Fibroscan |
| Abbott Laboratories | $20.65 | 2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $19.78 | 2025 | Wegovy |
| Ethicon US, LLC | $17.96 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.82 | 2019 | |
| Amgen INC. | $16.93 | 2019 | |
| Dova Pharmaceuticals | $12.71 | 2019 | |
| Daiichi Sankyo INC. | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Mittal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.